Expansion of clinical program with the Lambert Initiative
Avecho has announced its ongoing collaboration with leading Australian research group for cannabinoid therapeutics, the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, will expand to include a series of clinical trials examining new clinical indications for cannabidiol using Avecho’s CBD soft-gel capsule.
These candidate indications have emerged from pre-clinical and early-stage clinical studies conducted by the Lambert Initiative, and represent attractive indications for future CBD products registered as over-the-counter (OTC) medicines with the Therapeutic Goods Administration (TGA).
Academic Director of the Lambert Initiative, Professor Iain McGregor, said:
“We have early evidence supporting the use of CBD in a number of new clinical indications and intend to examine these further in human clinical trials. We have been impressed by both the products, and the quality of the science, emerging from Avecho. Consequently, we are delighted to continue our productive collaboration with the company to use their oral CBD product for our forthcoming clinical trials examining novel indications.”
The studies will take place in Q3 2023, with preparatory work already underway. In total, Avecho’s products will be used in seven different clinical trials in 2023 including its pivotal Phase III insomnia trial, which received ethics approval late last year.